Pipeline Overview
Click to learn about the trilaciclib mechanism of action
G1 is advancing its lead clinical compound trilaciclib, a first-in-class therapy designed to improve outcomes for patients who are treated with chemotherapy, in clinical trials assessing myeloprotection and anti-tumor efficacy endpoints in a variety of tumors including colorectal cancer (CRC), metastatic triple negative breast cancer (TNBC), neoadjuvant breast cancer, non-small cell lung cancer (NSCLC) and bladder cancer.
d. Phase 1b data presented at ASCO
The safety and efficacy of investigational agents or an investigational use of an approved product have not been established or approved by the FDA or other regulatory authorities.